Overexpression of S100A4 conferred human cancer cell lines resistant to the chemotherapeutic drug methotrexate (Mencía et al., 2010) and suppression of the S100A4 gene increased sensitivity of pancreatic cancer cells to gemcitabine treatment (Mahon et al., 2007). Here, S100A4 is linked to familial pancreatic carcinoma.